Julien Durigneux

Angers, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.

Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.

Journal: JAMA network open
Published: October 08, 2025

Phenotype-specific muscle proteomic profiling in titinopathies.

Phenotype-specific muscle proteomic profiling in titinopathies.

Journal: Acta neuropathologica communications
Published: September 12, 2025

Laminopathies: natural history and risk prediction of heart failure.

Laminopathies: natural history and risk prediction of heart failure.

Journal: European heart journal
Published: June 06, 2025

Evaluation of professional practices in the use of mexiletine for the management of childhood myotonia in French pediatric neuromuscular centers (MEXI-PEDI survey).

Evaluation of professional practices in the use of mexiletine for the management of childhood myotonia in French pediatric neuromuscular centers (MEXI-PEDI survey).

Journal: Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
Published: October 05, 2023

Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment.

Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment.

Journal: Orphanet journal of rare diseases
Published: May 09, 2023

Evaluation of safety of fluoxetine for cerebellar mutism syndrome in children after posterior fossa surgery.

Evaluation of safety of fluoxetine for cerebellar mutism syndrome in children after posterior fossa surgery.

Journal: Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
Published: April 01, 2023

Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type.

Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type.

Journal: Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
Published: January 30, 2023

Correction to: Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.

Correction to: Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: November 23, 2022

Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.

Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: June 17, 2022

The lncRNA 44s2 Study Applicability to the Design of 45-55 Exon Skipping Therapeutic Strategy for DMD.

The lncRNA 44s2 Study Applicability to the Design of 45-55 Exon Skipping Therapeutic Strategy for DMD.

Journal: Biomedicines
Published: January 20, 2021

Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen.

Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen.

Journal: Pediatric pulmonology
Published: September 14, 2020

Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports.

Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports.

Journal: Frontiers in pediatrics
Published: October 09, 2019
Showing 1-12 of 19

Last Updated: 09/26/2026